AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8021040 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice
Number of subjects: 194
Study 8021040 — intervention group
Group type: COMPARATOR
Intervention: Triclosan/soluble pyrophosphate dentifrice
Number of subjects: 194
Study 8021040 — intervention group
Group type: COMPARATOR
Intervention: Triclosan/zinc citrate dentifrice
Number of subjects: 194
Study 8021040 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 194
Study 2812979 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ergometer exercise at 30% heart-rate reserve
Number of subjects: 24
Study 2812979 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ergometer exercise at 60% heart-rate reserve
Number of subjects: 24
Study 1036963 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol
Number of subjects: 0
Study 1036963 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 0
Study 1036963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketobemidone
Number of subjects: 0
Study 1036963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30476335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention tools (e.g., prompts and standing desks)
Number of subjects: 0
Study 30476335 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in number of tools
Number of subjects: 0
Study 31009470 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (5 sessions by an acupuncturist midwife)
Number of subjects: 199
Study 31009470 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 199
Study 31009470 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 199
Study 28598913 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% xenon adjuvant to propofol anesthesia
Number of subjects: 50
Study 28598913 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 50
Study 27589584 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 2
Study 27589584 — intervention group
Group type: COMPARATOR
Intervention: Very-low-calorie diet
Number of subjects: 2
Study 24456128 — intervention group
Group type: COMPARATOR
Intervention: Breast irradiation (50 Gy in 25 fractions)
Number of subjects: 688
Study 24456128 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologically equivalent dose (BED) Gy3 ≥ 80 Gy
Number of subjects: 688
Study 24456128 — intervention group
Group type: EXPERIMENTAL
Intervention: BED Gy3 ≥ 80 Gy
Number of subjects: 688
Study 23016867 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (MTZ) 400 mg thrice a day (TID) for 14 days
Number of subjects: 118
Study 23016867 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole + Amoxicillin (MTZ+AMX) 500 mg TID for 14 days
Number of subjects: 118
Study 23016867 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine 0.12% rinsed twice a day (BID) for 2 months
Number of subjects: 118
Study 23016867 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only
Number of subjects: 118
Study 18801487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) for 24 weeks
Number of subjects: 134
Study 18801487 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 134
Study 18801487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 134
Study 18801487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 18801487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) and Placebo
Number of subjects: 134
Study 18004925 — intervention group
Group type: EXPERIMENTAL
Intervention: UltraEZ potassium nitrate desensitizer
Number of subjects: 45
Study 18004925 — intervention group
Group type: EXPERIMENTAL
Intervention: BisBlock oxalate desensitizer
Number of subjects: 45
Study 18004925 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated enamel)
Number of subjects: 45
Study 15347540 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver
Number of subjects: 22
Study 15347540 — intervention group
Group type: COMPARATOR
Intervention: Placebo maneuver
Number of subjects: 22
Study 11481402 — intervention group
Group type: EXPERIMENTAL
Intervention: Touchi-extract (TE) 0.3 g before each meal for 3 months
Number of subjects: 36
Study 11481402 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Houji-tea without TE)
Number of subjects: 36
Study 9951916 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) 5 MU TIW SQ for 6 months
Number of subjects: 40
Study 9951916 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine infused at a dose of 80 mg/kg per cycle
Number of subjects: 40
Study 7850395 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 140
Study 7850395 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral ECT
Number of subjects: 140
Study 7850395 — intervention group
Group type: COMPARATOR
Intervention: Normal EEG
Number of subjects: 140
Study 7850395 — intervention group
Group type: COMPARATOR
Intervention: Abnormal EEG
Number of subjects: 140
Study 2853753 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg once a day)
Number of subjects: 24
Study 2853753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1841828 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (20 mg/kg loading dose)
Number of subjects: 12
Study 1841828 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study 594674 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (total dose of 3,300 rads in 3 weeks)
Number of subjects: 88
Study 594674 — intervention group
Group type: COMPARATOR
Intervention: Nephrectomy-only (control group)
Number of subjects: 88
Study 31489842 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized prompts via mHealth app
Number of subjects: 69
Study 28142202 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox film-coated tablet (FCT)
Number of subjects: 173
Study 28142202 — intervention group
Group type: COMPARATOR
Intervention: Deferasirox dispersible tablets (DT)
Number of subjects: 173
Study 26313463 — intervention group
Group type: COMPARATOR
Intervention: D1 dissection group
Number of subjects: 1078
Study 26313463 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 dissection group
Number of subjects: 1078
Study 26313463 — intervention group
Group type: COMPARATOR
Intervention: D1 group with major non-compliance
Number of subjects: 1078
Study 26313463 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 group with major non-compliance
Number of subjects: 1078
Study 26313463 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 compliant + contaminated group
Number of subjects: 1078
Study 26313463 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 contaminated group
Number of subjects: 1078
Study 24010675 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2196044 (125 or 250 mg/d)
Number of subjects: 375
Study 24010675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 20941459 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg bid, 10 mg bid or 20 mg qd)
Number of subjects: 520
Study 20941459 — intervention group
Group type: COMPARATOR
Intervention: LMWH/VKA
Number of subjects: 520
Study 18583436 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA supplements
Number of subjects: 54
Study 18583436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 17485157 — intervention group
Group type: EXPERIMENTAL
Intervention: Social rejection
Number of subjects: 0
Study 17485157 — intervention group
Group type: COMPARATOR
Intervention: Social acceptance
Number of subjects: 0
Study 17485157 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 17485157 — intervention group
Group type: EXPERIMENTAL
Intervention: Defensiveness as a moderating factor
Number of subjects: 0
Study 15164169 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose treatment
Number of subjects: 61
Study 11441409 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m(2) plus cisplatin 75 mg/m(2) every 3 weeks
Number of subjects: 1220
Study 11441409 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m(2) plus carboplatin to an area under the curve of 6 mg/mL x min every 3 weeks
Number of subjects: 1220
Study 11441409 — intervention group
Group type: COMPARATOR
Intervention: vinorelbine 25 mg/m(2) weekly plus cisplatin 100 mg/m(2) monthly
Number of subjects: 1220
Study 9608923 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemisynthesis diosmine 600 mg, one tablet per day taken in the morning
Number of subjects: 255
Study 9608923 — intervention group
Group type: COMPARATOR
Intervention: Usual tablet formulation of diosmine 300 mg taken twice a day (morning and evening)
Number of subjects: 255
Study 8001524 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg retinol as retinyl palmitate every 4 months for 1 year
Number of subjects: 0
Study 8001524 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo) not specified
Number of subjects: 0
Study 2648213 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir, 800 mg 5 times daily for 7 days
Number of subjects: 83
Study 2648213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 30366387 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Worker Health® program, 'All the Right Moves'
Number of subjects: 607
Study 27941961 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar coagulation forceps
Number of subjects: 527
Study 27941961 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 527
Study 27941961 — intervention group
Group type: COMPARATOR
Intervention: Conventional thyroidectomy
Number of subjects: 527
Study 24557659 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-antimony sulfide colloid (ASC)
Number of subjects: 24
Study 24557659 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-filtered sulfur colloid (FSC)
Number of subjects: 24
Study 22093096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide (TAC)
Number of subjects: 40
Study 22093096 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) tattooing
Number of subjects: 40
Study 20217150 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 200 mg and imipramine 10 mg every 12 h orally (G400-I group)
Number of subjects: 52
Study 20217150 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 200 mg every 12 h orally (G400 group)
Number of subjects: 52
Study 20217150 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg every 12 h orally (G800 group)
Number of subjects: 52
Study 20217150 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 10 mg every 12 h orally (I group)
Number of subjects: 52
Study 18936501 — intervention group
Group type: EXPERIMENTAL
Intervention: NPL insulin
Number of subjects: 116
Study 18936501 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 116
Study 18936501 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Number of subjects: 116
Study 16048153 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibraject (vibrating dental local anesthesia attachment)
Number of subjects: 10
Study 16048153 — intervention group
Group type: COMPARATOR
Intervention: Control (standard injection without Vibraject)
Number of subjects: 10
Study 12443742 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive direct aortic surgery (MIDAS)
Number of subjects: 300
Study 12443742 — intervention group
Group type: COMPARATOR
Intervention: Conventional aorto-bifemoral by-pass surgery
Number of subjects: 300
Study 10100064 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measurement (SM) using an OMRON HEM706 oscillometric device
Number of subjects: 62
Study 10100064 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 62
Study 10100064 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received additional perindopril or indapamide
Number of subjects: 62
Study 10100064 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measurement (SM)
Number of subjects: 62
Study 8889438 — intervention group
Group type: EXPERIMENTAL
Intervention: E25 (Estraderm 25)
Number of subjects: 71
Study 8889438 — intervention group
Group type: EXPERIMENTAL
Intervention: E50 (Estraderm 50)
Number of subjects: 71
Study 2006119 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intramuscular polyestradiol phosphate (PEP) and oral ethinyl estradiol
Number of subjects: 477
Study 2006119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular PEP alone
Number of subjects: 477
Study 2006119 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy
Number of subjects: 477
Study 2006119 — intervention group
Group type: COMPARATOR
Intervention: Finnish male population (control group)
Number of subjects: 477
Study 6332893 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (twice daily for 6 months)
Number of subjects: 37
Study 6332893 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 6 months)
Number of subjects: 37
Study 31859575 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological mesh (Veritas®)
Number of subjects: 15
Study 31859575 — intervention group
Group type: COMPARATOR
Intervention: Synthetic mesh (TIGR® Matrix Surgical Mesh)
Number of subjects: 15
Study 31859575 — intervention group
Group type: EXPERIMENTAL
Intervention: Both biological and synthetic meshes
Number of subjects: 15
Study 28940481 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary (Bioteque cup pessary)
Number of subjects: 122
Study 28940481 — intervention group
Group type: COMPARATOR
Intervention: No pessary
Number of subjects: 122
Study 27422600 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised directional preference management plus guideline‐based advice
Number of subjects: 78
Study 27422600 — intervention group
Group type: COMPARATOR
Intervention: Advice alone
Number of subjects: 78
Study 25376862 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 901
Study 25376862 — intervention group
Group type: COMPARATOR
Intervention: In-person counseling
Number of subjects: 901
Study 22137185 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARX computerized Cognitive Behavioural Therapy (cCBT) completed over 5 weeks (n=20)
Number of subjects: 32
Study 22137185 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n=12)
Number of subjects: 32
Study 19770739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP) therapy
Number of subjects: 45
Study 19770739 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (without IABP)
Number of subjects: 45
Study 18030086 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 439
Study 18030086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 439
Study 18030086 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine and CBT
Number of subjects: 439
Study 18030086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study 18030086 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents
Number of subjects: 439
Study 16275871 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 5804
Study 16275871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5804
Study 12042265 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone orally followed by 800 microg vaginal misoprostol
Number of subjects: 250
Study 12042265 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by 800 microg vaginal misoprostol
Number of subjects: 250
Study 12042265 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol regimen
Number of subjects: 250
Study 10084721 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive discharges (RDs) observed in lower motor neuron lesions
Number of subjects: 0
Study 10084721 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude of the second component of RDs
Number of subjects: 0
Study 10084721 — intervention group
Group type: EXPERIMENTAL
Intervention: Jitter of the components of RDs
Number of subjects: 0
Study 7570567 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (0.1 microgram/kg/min)
Number of subjects: 20
Study 7570567 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (bolus 1 mg/kg, continuous infusion of 5‐10 micrograms/kg/min)
Number of subjects: 20
Study 2160667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive combined chemotherapy (B)
Number of subjects: 99
Study 2160667 — intervention group
Group type: COMPARATOR
Intervention: High-dose half-body irradiation (HBI) (A)
Number of subjects: 99
Study 2160667 — intervention group
Group type: COMPARATOR
Intervention: Local or locoregional radiotherapy (C)
Number of subjects: 99
Study 6448131 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1 percent clindamycin phosphate (Cleocin T)
Number of subjects: 50
Study 6448131 — intervention group
Group type: COMPARATOR
Intervention: Oral tetracycline 500 mg/day
Number of subjects: 50
Study 30826273 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem-cell transplantation
Number of subjects: 228
Study 30826273 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 228
Study 30826273 — intervention group
Group type: COMPARATOR
Intervention: High minimal residual disease
Number of subjects: 228
Study 30826273 — intervention group
Group type: COMPARATOR
Intervention: Low minimal residual disease
Number of subjects: 228
Study 27513532 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse‐led, goal‐directed sedation protocol
Number of subjects: 1157
Study 27513532 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1157
Study 26267721 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% tofacitinib
Number of subjects: 81
Study 26267721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% tofacitinib
Number of subjects: 81
Study 26267721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% tofacitinib
Number of subjects: 81
Study 26267721 — intervention group
Group type: COMPARATOR
Intervention: Vehicle solution
Number of subjects: 81
Study 23537750 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose sodium picosulphate/magnesium oxide/anhydrous citric acid (Citrafleet(®)) regimen administered 2 to 6 hours before colonoscopy
Number of subjects: 193
Study 23537750 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose sodium picosulphate/magnesium oxide/anhydrous citric acid (Citrafleet(®)) regimen
Number of subjects: 193
Study 21323461 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive posthospitalization nurse-led interdisciplinary care management
Number of subjects: 530
Study 21323461 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized, evidence-based medical and psychosocial intervention protocols
Number of subjects: 530
Study 21323461 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic illness management intervention
Number of subjects: 530
Study 19118083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg twice daily for 9 days, coadministered with a single 5‐mg dose of fingolimod on the 4th day of ketoconazole treatment.
Number of subjects: 22
Study 19118083 — intervention group
Group type: COMPARATOR
Intervention: Fingolimod 5 mg single dose in period 1 without ketoconazole.
Number of subjects: 22
Study 17552958 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day frequency-volume chart (FVC)
Number of subjects: 140
Study 16734123 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sICAM‐1 levels in chronic HCV patients
Number of subjects: 57
Study 16734123 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sICAM‐1 levels in NBNC-CLD patients
Number of subjects: 57
Study 16734123 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels in HCV-RNA positive patients
Number of subjects: 57
Study 16734123 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels correlation with ALT
Number of subjects: 57
Study 16734123 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels correlation with AST
Number of subjects: 57
Study 16734123 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels correlation with prothrombin time
Number of subjects: 57
Study 16734123 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels correlation with alkaline phosphatase
Number of subjects: 57
Study 16734123 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels correlation with albumin
Number of subjects: 57
Study 16734123 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels correlation with clinical findings in chronic HCV patients
Number of subjects: 57
Study 16734123 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels and Knodell score
Number of subjects: 57
Study 11223701 — intervention group
Group type: COMPARATOR
Intervention: First trimester pregnant women
Number of subjects: 30
Study 11223701 — intervention group
Group type: COMPARATOR
Intervention: Third trimester pregnant women
Number of subjects: 30
Study 9599555 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioselective beta 1 antagonists for more than three months
Number of subjects: 40
Study 9599555 — intervention group
Group type: COMPARATOR
Intervention: Control group (never received beta-blockers)
Number of subjects: 40
Study 9599555 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioselective beta 1 antagonists
Number of subjects: 40
Study 9208342 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms cerivastatin as a 1-minute bolus infusion
Number of subjects: 12
Study 9208342 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms cerivastatin orally as tablets
Number of subjects: 12
Study 9208342 — intervention group
Group type: COMPARATOR
Intervention: 200 micrograms cerivastatin as an oral solution
Number of subjects: 12
Study 1901072 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 270
Study 1901072 — intervention group
Group type: COMPARATOR
Intervention: Recombinant tissue-type plasminogen activator (rt-PA)
Number of subjects: 270